January 18, 2021
Business News

Bristol Myers Squibb and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myeloma at ASH 2020


PRINCETON, N.J. & CAMBRIDGE, Mass.–()–Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced updated data evaluating the companies’ investigational B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR) T cell therapy, idecabtagene vicleucel (ide-cel), were presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition. The data include longer-term updated results from the original Phase 1 CRB-401 study of ide-cel in relapsed and refractory multiple myeloma (RRMM), including the primary endpoint of safety and exploratory endpoints of progression-free survival (PFS) and overall survival (OS). Analyses of the pivotal registrational…



Click here to view the original article.

Related Posts

You might also like ...

DMS Announces #1 Rank On Best CPA Networks For Advertisers List
Global Non-Small Cell Lung Cancer Clinical Trial Pipeline Report 2021 – ResearchAndMarkets.com
Electric Hoist Market Research Report – Global Forecast to 2024 – Cumulative Impact for COVID-19 Recovery | SpendEdge